Skip to main content
Signal8

ALTERITY THERAPEUTICS LTD (ATHE) Form 6-K — Nov 12, 2026

$ATHEForm 6-KFiled Nov 12, 2026, 6:01 AM ET0001437749-26-036287Original filing

Alterity Therapeutics announced that CEO David Stamler will present at the virtual Bell Potter Healthcare Conference on November 19, 2026, with an archived webcast to be posted on the company's website. The company confirmed it is preparing to initiate a Phase 3 pivotal trial of ATH434 in Multiple System Atrophy, a rare neurodegenerative disease with no approved treatment, following positive Phase 2 data.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    ALTERITY THERAPEUTICS LTD (ATHE) Form 6-K — Nov 12, 2026: AI Analysis | Signal8